Q32 Bio Inc. (QTTB)
Q32 Bio develops experimental antibody treatments for alopecia areata and other autoimmune and inflammatory diseases. It last closed at $8.63 on Nov 17, up 4.10% on the day. The average 12-month price target from 3 analysts is $34.33 (+297.8% from the last close), with a high of $40.00 and a low of $29.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Fiscal 2025Not reported for this period.
From QTTB's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 4).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on QTTB in the past 90 days. The average target is $34.33, with a high of $40.00 and a low of $29.00, compared with the last close of $8.63.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | Leerink Partners | Initiated | Buy | $40 |
| Sep 28 | Jefferies | Initiated | Buy | $29 |
| Aug 24 | Morgan Stanley | Initiated | Buy | $34 |
| Jul 28 | HC Wainwright & Co. | Maintained | Buy | $36 |
| Jul 13 | Wells Fargo | Upgrade | Buy | $66 |
Technical Analysis
The stock is 3% below its 20 day and 5% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $8.47, and the nearest resistance the 20 day average at $8.85.
| RSI (14) | 45.01 | Middle of its range | Neutral |
| MACD | -0.12 | Above its signal line | Bullish |
| Stochastic | 23.1 | Middle of its range | Neutral |
| ADX (14) | 17.9 | No clear trend | |
| Williams %R | -66.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -114.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −1.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.56 | Typical daily range, 6.4% of price |
| RSI (14) | 44.35 | Middle of its range | Neutral |
| MACD | -0.30 | Below its signal line | Bearish |
| Stochastic | 16.3 | Near the bottom of its range | Oversold |
| ADX (14) | 31.4 | Trending up | |
| Williams %R | -86.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -74.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −22.3% | Change over 10 sessions | Bearish |
| ATR (14) | $1.91 | Typical daily range, 22.1% of price |
What happened before
See how QTTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How QTTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in QTTB in the last 90 days.
QTTB Institutional Ownership
Full report →- ▲71 buying vs 32 selling
- ▲Held by funds +31.1 pts
- ▲Funds holding +33
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 105 | 72 | +45.8% |
| In funds' top 10 | 1 | 3 | −66.7% |
| Held by funds | 105.3% | 74.2% | +31.1 pts |
| New / increased | 48 / 23 | 28 / 18 | +54.3% |
| Reduced / sold out | 16 / 16 | 13 / 8 | +52.4% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QTTB is in one of them and how their past QTTB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered QTTB in an article yet. Here's the latest on the wider market.
About Q32 Bio
Q32 Bio is a biotechnology company in Waltham, Massachusetts, that develops experimental biologic medicines for patients with alopecia areata, a condition that causes hair loss, and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is an antibody designed to block two immune signals and is being tested in clinical trials. The company also holds a tissue-targeted complement inhibitor platform, which it is evaluating for strategic options.
- Headquarters
- Waltham, MA



